The mechanism whereby glucocorticosteroids are immunosuppressive is unknown. One potential mechanism of action of these compounds is inhibition of arachidonic acid metabolism. We found that the inhibition of lymphocyte proliferation by hydrocortisone or dexamethasone was mimicked by nonspecific lipoxygenase inhibitors and also by a specific 5-lipoxygenase inhibitor, but not by a specific cyclooxygenase inhibitor. Mitogen-stimulated cultures of T cells produce -5 X 10-9 M leukotriene B4 (LTB4) in 24 h. This production of LTB4 is completely inhibited by concentrations of hydrocortisone or lipoxygenase inhibitors that inhibit mitogen-induced VHjthymidine incorporation. The inhibition of lymphocyte proliferation by either hydrocortisone or by the 5-lipoxygenase inhibitor was totally reversed by LTB4 but not by leukotriene C4 or leukotriene D4. LTB4 had no effect on the inhibition of lymphocyte proliferation by noncorticosteroids such as prostaglandin E2, histamine, or y-interferon. The inhibition of interleukin 2 (IL-2) production by hydroccrtisone or dexamethasone was also completely reversed by exogenous LTB4.
Introduction
While the powerful effects of glucocorticosteroids (hereafter referred to as corticosteroids) on immune function have been recognized almost since their discovery in 1948, the mechanism of action of these drugs (or endogenous hormones) has been unclear. In 1975, Gryglewski et al. (1) and several other groups (2) (3) (4) showed that corticosteroids inhibit the release of arachidonic acid from membrane phospholipids and proposed that their antiinflammatory activity is due to this action. This hypothesis was difficult for many investigators to accept because it was already generally accepted that nonsteroidal antiinflammatory agents (NSAIA)' work via inhibition of arachidonic acid metabolism, 1. Abbreviations used in this paper: FCS, fetal calf serum; HETE, hydroxyeicosatetraenoic acid; HPLC, high performance liquid chromatography; IL-2, interleukin 2; LTB4, leukotriene B4; LTC4, leukotriene C4; and that the antiinflammatory effects ofcorticosteroids are clearly different and more powerful than those of NSAIA. The understanding of arachidonic acid metabolism at that time was essentially as a straight line synthetic pathway from membrane phospholipid to arachidonic acid to the prostaglandins. Thus, if corticosteroids and NSAIA inhibit at different points in the same pathway, they should have very similar actions. This problem was clarified when Samuelsson and others (5) identified the lipoxygenase metabolic pathways for arachidonic acid.
This more complex schema of arachidonic acid metabolism allows us to seriously consider the possibility that many of the pharmacologic and perhaps physiologic actions ofcorticosteroids are indeed via inhibition of arachidonic acid release from membrane phospholipid, because corticosteroids inhibit both cyclooxygenase and lipoxygenase products while NSAIA inhibit only cyclooxygenase products. Clearly, the evidence supporting this concept has grown considerably over the past few years. Danon and Assouline (6) showed that RNA and protein synthesis are required in order for steroids to inhibit prostaglandin production. In 1979 and 1980, Flower and his associates (7, 8) in England and Hirata, Axelrod, and their co-workers (9) at the National Institutes of Health identified a phospholipase A2-inhibitory glycoprotein, termed macrocortin or lipomodulin, that is synthesized and released by cells upon exposure to corticosteroids. On the other hand, several investigators have failed to find an inhibition by corticosteroids of the endogenous production of arachidonic acid metabolites in vitro (10) and in vivo (11, 12) .
In this paper we show that mitogen-stimulated T cells produce substantial amounts of the 5-lipoxygenase product, leukotriene B4 (LTB4). Concentrations of hydrocortisone or dexamethasone which inhibit mitogen-induced [3H]thymidine incorporation and interleukin 2 (IL-2) synthesis also inhibit LTB4 production. In addition, nonspecific lipoxygenase inhibitors and a specific 5-lipoxygenase inhibitor also inhibit the mitogen response. Finally, readdition of LTB4 in concentrations normally produced to cultures containing hydrocortisone reverses the inhibition by hydrocortisone of IL-2 production and mitogen-induced proliferation ofT cells. These findings support the concept that corticosteroids inhibit T cell proliferation via phospholipase A2 inhibition; specifically, that corticosteroids inhibit mitogeninduced T cell proliferation by suppressing endogenous LTB4 production.
Methods
Drugs. LTB4 Isolation ofperipheral blood lymphocytes. Peripheral blood mononuclear cells were isolated on Ficoll-Hypaque density gradients (Pharmacia Fine Chemicals, Piscataway, NJ) from heparinized blood ofhealthy adult donors. Glass-adherent cells were removed by incubation at 370C for I h on glass petri dishes in RPMI 1640 with 20% fetal calf serum (FCS). T cells were isolated from these nonadherent cells by rosetting with 2-aminoethylisothio-uranium bromide hydrobromide-treated sheep red blood cells followed by centrifugation over Ficoll-Hypaque for 30 min at 300 g. The sheep red blood cells were lysed with Tris-NHCl buffer. The cell population, termed T cells, contained 95% T cells, as identified by the pan-T monoclonal reagent Leu-5, and 1-2% peroxidasepositive cells.
In some experiments the T cells were exposed to 500 rads irradiation using a 2560 Maximar III, 250 KV X-ray system (General Electric Co., Milwaukee, WI). After irradiation, cells were washed and resuspended in fresh medium for culture.
Cell Measurement ofLTB4 production. Cultures of T cells, 106 cells/ml, were established in 10 X 75-mm culture tubes (2054; Falcon Labware, Becton, Dickinson & Co., Oxnard, CA) with or without sera. After 0 or 24 h, culture media were harvested and processed for leukotriene extraction, high pressure liquid chromatographic separation, and quantification by radioimmunoassay (RIA). Media, 1 ml, were spiked with 1,800-2,000 cpm of purified 3H[LTB4] (specific gravity 32 Ci/mmol) to calculate recoveries. In a first step, media were extracted using 0.5 vol of isopropanol. They were then acidified with formic acid (5 M to a pH of 3.0-3.5) and a second extraction was performed using 2.5 vol ofdiethyl ether. After centrifugation and phase separation, the organic phase (isopropanol/diethyl ether) was removed and the aqueous was reextracted with 2.5 vol of diethyl ether. The organic phases were pooled, dried under a nitrogen stream, and reconstituted in I ml of methanol/water Fig. 2 shows the effect of delaying LTB4 addition to PHAstimulated cultures containing hydrocortisone. Addition of LTB4 up to 8 h after initiation of the culture still resulted in complete reversal of the inhibition by hydrocortisone, while after 16 h of culture, addition of LTB4 had little effect on hydrocortisone inhibition. Also, when the cells were preincubated with hydrocortisone for 2 h and then washed, addition of LTB4 after the washing still reversed the inhibition caused by hydrocortisone (data not shown). Table III shows data suggesting that the reversal of inhibition of T cell proliferation by LTB4 is specific for corticosteroids. LTB4 did not reverse inhibition of [3H]thymidine incorporation caused by PGE2, histamine, -y-interferon, or y-irradiation, but did reverse the inhibition caused by hydrocortisone or dexamethasone. [3H]thymidine incorporation. This inhibition was completely reversed by addition of LTB4 (10-'°M) at the beginning of the culture or 2, 4, 6, or 8 h after beginning the culture. If LTB4 addition was delayed for 18 h or longer it had little or no effect on hydrocortisone inhibition of T cell proliferation.
component of mitogen-stimulated T cell proliferation. Accordingly, we measured LTB4 levels in these cultures. Fig. 3 shows a representative high performance liquid chromatography (HPLC) analysis ofthe supernates ofT cells cultured without (A) or with (B) PHA for 24 h. In the supernates from the T cells cultured with PHA there was a large peak at the retention time comparable to LTB4. Elution fractions corresponding to this peak were collected and assayed for immunoreactive LTB4 using an RIA. These results are presented in Table  IV and show that the LTB4 peak seen in Fig. 3 with PHA (B). The major peak in the supernate from the PHA-stimulated T cell culture had a retention time identical to LTB4 and corresponded to the peak of immunoreactive LTB4 by RIA (see Table IV ). There were additional smaller peaks with retention times identical to 12-HETE and 5-HETE in the HPLC analysis of the PHA-stimulated culture that were lacking in the control cultures. 1O-6 or of specific or nonspecific lipoxygenase inhibitors completely eliminated LTB4 production (Table IV) and inhibited by >90% the production of other arachidonic acid metabolites (5-HETE, l2-HETE, and 1 5-HETE; data not shown). Hydrocortisone at 10-0 and 10-8 M caused lesser inhibition of LTB4 production (Table IV) . This parallels the less potent inhibition oflymphocyte proliferation by l0-M hydrocortisone (Table II) . Corticosteroids have been shown to inhibit IL-2 production, and exogenous IL-2 reverses the inhibition of mitogen-induced T cell proliferation by corticosteroids (46) (47) (48) (49) . To explore the relationship between LTB4 and IL-2, we examined the effect of hydrocortisone and LTB4 on IL-2 production by mitogen-stimulated T cells. As shown in Table V , inhibition ofIL-2 production by hydrocortisone is reversed by exogenous LTB4. There is a clear dose-response relationship, with an effect as low as 10-14 M LTB4. PGE2 or LTC4 did not affect the inhibition of IL-2 production by hydrocortisone.
Discussion
In order to conclude that the effects of corticosteroids in a given physiologic system are due to inhibition ofarachidonic acid metabolism, several criteria should be met. First, one should demonstrate that corticosteroids do indeed inhibit arachidonic acid metabolism in the system under study. Second, one should be able to duplicate the effect of corticosteroids with drugs which inhibit all the metabolic pathways for arachidonic acid. If so, then it might also be possible to find a more specific inhibitor ofarachidonic acid metabolism, such as a specific cyclooxygenase inhibitor or a specific inhibitor of one of the lipoxygenase enzymes, that duplicates the effects of corticosteroids in the physiologic system. Third, one should be able to reverse the effect of corticosteroids by adding back one or more specific arachidonic acid metabolites to the system, such as PGE, LTC4, 1 5-hydroperoxyeicosatetraenoic acid, etc. In this present communication we found that, while exogenous LTB4 by itself caused slight inhibition of T cell proliferation, LTB4 added in the first 8 h of culture completely overcame the much more dramatic inhibition caused by hydrocortisone or dexamethasone. LTB4 is normally produced in mitogenstimulated T cell cultures and this production is completely inhibited by concentrations of hydrocortisone that inhibit [3H]thymidine incorporation. Other drugs that inhibit LTB4 production, such as specific and nonspecific lipoxygenase inhibitors, also inhibit the mitogen response, and exogenous LTB4 can reverse that inhibition. We conclude that endogenous LTB4 production early in the culture is necessary for mitogen-stimulated T cell proliferation and that corticosteroids inhibit T cell proliferation by reducing endogenous LTB4 production. Addition of LTB4 to mitogen-stimulated T cells cultured without hydrocortisone has little effect, presumably because there are already optimal levels of LTB4 produced endogenously.
LTB4 is produced by enzymatic hydrolysis ofleukotriene A4 which is labile epoxide resulting from oxidation of arachidonic acid at the 5 position (5). LTB4 has powerful chemoattractant and aggregating properties for neutrophils (21, 22). There have been few reports suggesting a role for LTB4 in cellular immune responses. Several laboratories have reported modest (23) (24) (25) or no (26) inhibition of mitogen-stimulated proliferation ofhuman T cells by LTB4 or by LTC4 (27) . In addition, Rola-Plezczynski et al. (23) and we (28) have found that LTB4 causes induction of suppressor T cells. Several years ago Kelly et al. (29) reported that nonspecific lipoxygenase inhibitors such as NDGA inhibited mitogen-induced proliferation. Johnson and Torros (30) found that LTB4, LTC4, or LTD4 could replace the requirement for IL-2 for interferon production by murine splenocytes. In another study, we found that LTB4 can act synergistically with suboptimal levels of IL-2 in stimulating proliferation of IL-2 responsive cells (3 1) .
While LTB4 has been identified as a major arachidonic acid metabolite of polymorphonuclear leukocytes (32), monocytemacrophages (33) (34) (35) , basophils (36) , and eosinophils (37), it has not been well accepted that purified T cells produce LTB4 or, indeed, any arachidonic acid metabolites (35, (38) (39) (40) (41) (42) . Parker et al. (43) reported in 1979 that lymphocytes metabolized arachidonic acid to 5-HETE, but their lymphocyte preparations contained substantial numbers of monocytes and some neutrophils. Goetzl (44) reported that human T cells (E-rosette positive) stimulated with concanavalin A or a calcium ionophore produce substantial amounts of 5-lipoxygenase metabolites, including LTB4, but others have disputed this claim (35, 38, 45) , arguing that the LTB4 produced comes from contaminating monocytes in the T cell preparation. We view this as an unlikely explanation for our results for several reasons. First, LTB4 was produced only in conjunction with the T cell mitogen PHA and not by resting cells (Fig. 3 and Table IV ). Second, the percentage of contaminating monocytes in our preparations was <2%; in further experiments (Atluru, D., E. Lianos, and J. S. Goodwin, manuscript submitted for publication) we found that adding back increasing numbers of monocytes to the T cells, to a final concentration of 20% monocytes, did not increase the LTB4 produced upon PHA stimulation. We feel that previous efforts to determine if lymphocytes produce LTB4 may have failed because the investigators added high concentrations of exogenous arachidonic acid to their cell cultures (35) . We have found that exogenous arachidonic acid from l0-' to IO-9 M inhibits LTB4 and 5-HETE production by PHA-stimulated T cells by >90% (45a). Laclos and his colleagues (46) have recently reported a similar phenomenon of inhibition of 5-lipoxygenase in human neutrophils by exogenous arachidonic acid.
There is a seeming discrepancy between the amount of the LTB4 required to restore T cell proliferation or IL-2 production in cultures containing hydrocortisone ( Fig. 1 and Table V ) and the amount of the LTB4 production actually produced in the cultures not containing hydrocortisone (Table IV) . Much more LTB4 is produced than would appear necessary to maintain IL-2 production and T cell proliferation. We feel part of this discrepancy is due to the fact that we measured LTB4 production at 18 h, whereas the effect of endogenous LTB4 is early, at least within the first 8 h of culture, based on the data in Fig. 2 . The early LTB4 production in the first minutes ofthe culture is below the sensitivity of our assay, but, by extrapolation, is presumably in the range (I0-Io-l012 M) that causes restoration of IL-2 production and T cell proliferation when added to PHA-stimulated cultures containing hydrocortisone.
Corticosteroids have been shown to inhibit IL-2 production, and exogenous IL-2 reverses the inhibition of mitogen-induced T cell proliferation by corticosteroids (47) (48) (49) (50) . Thus, either LTB4 or IL-2 reverses the inhibition of T cell proliferation caused by corticosteroids. As shown in Table V , exogenous LTB4 restores IL-2 production by PHA-stimulated T cells cultured with hydrocortisone. Thus, we conclude that in T cell proliferation, LTB4 production is a necessary step in IL-2 production. Corticosteroids, by inhibiting LTB4 production, also inhibit IL-2 production, resulting in decreased T cell proliferation. The effect of corticosteroids on T cell proliferation can be overcome by adding LTB4, thus restoring endogenous IL-2 production to normal, or by adding IL-2 directly. Our findings suggest that specific 5-lipoxygenase inhibitors or specific LTB4 antagonists might possess immunosuppressive properties similar to corticosteroids, while, because of their specificity, they might not share many of the other physiologic effects of corticosteroids.
